Cord Blood America Visits China; Sets 2010 Goals: Acquisitions, Diversification, Organic Growth

LAS VEGAS, Feb. 22 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy, for families nationwide and internationally, said today in an interview of Matthew Schissler, co-founder and CEO, by analyst Francis Gaskins, that its goal is to be the world's largest stem cell storage facility.  

The entire interview is available at http://gaskinsco.com/cbai-2-18-10.mp3

Mr. Schissler said he recently returned from a business trip to China where, he said, the acceptance of the need to store stem cells may be even greater than in the U.S.  "It is an intriguing market," Mr. Schissler said.

He explained that in recent news releases Cord Blood America will utilize its Las Vegas laboratory to store stem cells for a major Latin American firm and new sales representatives from Florida is part of the 2010 effort to diversify the revenue stream to not be solely reliant on its own cord blood storage service.  The other two 2010 goals are to increase organic growth and to find excellent acquisitions, for which we have a great appetite, Cord Blood America's co-founder said.

He said the Company will focus on adding storage of additional types of stem cells, including adipose tissue, placenta, bone marrow and others in 2010.  "Our goal is simple:  We want to be the dominant biological storage facility," Mr. Schissler said.

Cord Blood America's CEO also carefully explained the Company's successful 2009 effort to retire all its onerous debt and strengthen its balance sheet, and its new systems that significantly reduce any chance of contamination, which, Mr. Schissler said, gives Cord Blood America a distinct competitive advantage.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate,'' "believe,'' "expect,'' "future,'' "intend,'' "plan,'' and similar expressions to identify forward-looking statements. These statements, including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

SOURCE Cord Blood America, Inc.